Table. 2.
Characteristics of the laboratories
| Number of participants (%) | ||||||||
|---|---|---|---|---|---|---|---|---|
| AFP | CA125 | CA19-9 | CEA | PSA | T3 | Free T4 | TSH | |
| Labs performing tests | 84 (100.0) | 79 (100.0) | 82 (100.0) | 84 (100.0) | 85 (100.0) | 86 (100.0) | 86 (100.0) | 86 (100.0) |
| Average tests per month | ||||||||
| > 2,000 | 28 (33.3) | 12 (15.2) | 27 (32.9) | 29 (34.5) | 19 (22.4) | 36 (41.9) | 54 (62.8) | 55 (64.0) |
| 1,001–2,000 | 19 (22.6) | 8 (10.1) | 14 (17.1) | 18 (21.4) | 8 (9.4) | 16 (18.6) | 11 (12.8) | 11 (12.8) |
| 501–1,000 | 18 (21.4) | 13 (16.5) | 18 (22.0) | 16 (19.0) | 30 (35.3) | 17 (19.8) | 9 (10.5) | 10 (11.6) |
| 101–500 | 15 (17.9) | 35 (44.3) | 18 (22.0) | 17 (20.2) | 21 (24.7) | 12 (14.0) | 10 (11.6) | 8 (9.3) |
| ≤ 100 | 4 (4.8) | 11 (13.9) | 5 (6.1) | 4 (4.8) | 7 (8.2) | 5 (5.8) | 2 (2.3) | 2 (2.3) |
| Assay | ||||||||
| Roche | 46 (54.8) | 47 (59.5) | 49 (59.8) | 47 (56.0) | 45 (52.9) | 49 (57.0) | 49 (57.0) | 49 (57.0) |
| Abbott | 17 (20.2) | 17 (21.5) | 15 (18.3) | 17 (20.2) | 18 (21.2) | 19 (22.1) | 19 (22.1) | 19 (22.1) |
| Siemens | 15 (17.9) | 11 (13.9) | 12 (14.6) | 14 (16.7) | 13 (15.3) | 15 (17.4) | 15 (17.4) | 15 (17.4) |
| Beckman Coulter | 5 (6.0) | 3 (3.8) | 5 (6.1) | 5 (6.0) | 7 (8.2) | 3 (3.5) | 3 (3.5) | 3 (3.5) |
| Ortho Clinical Diagnostics | 1 (1.2) | 1 (1.3) | 1 (1.2) | 1 (1.2) | 1 (1.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Labs performing delta check | 30 (35.7) | 27 (34.2) | 28 (34.1) | 30 (35.7) | 33 (38.8) | 32 (37.2) | 32 (37.2) | 32 (37.2) |
| Average tests per month | ||||||||
| > 2,000 | 10 (11.9) | 11 (13.9) | 10 (12.2) | 10 (11.9) | 8 (9.4) | 13 (15.1) | 22 (25.6) | 22 (25.6) |
| 1,001–2,000 | 6 (7.1) | 2 (2.5) | 2 (2.4) | 6 (7.1) | 2 (2.4) | 8 (9.3) | 3 (3.5) | 3 (3.5) |
| 501–1,000 | 7 (8.3) | 7 (8.9) | 7 (8.5) | 8 (9.5) | 15 (17.6) | 6 (7.0) | 2 (2.3) | 2 (2.3) |
| 101–500 | 5 (6.0) | 6 (7.6) | 7 (8.5) | 4 (4.8) | 5 (5.9) | 2 (2.3) | 4 (4.7) | 4 (4.7) |
| ≤ 100 | 2 (2.4) | 1 (1.3) | 2 (2.4) | 2 (2.4) | 3 (3.5) | 3 (3.5) | 1 (1.2) | 1 (1.2) |
| Labs performing panic check | 39 (46.4) | 37 (46.8) | 42 (51.2) | 42 (50.0) | 39 (45.9) | 32 (37.2) | 31 (36.0) | 34 (39.5) |
| Average tests per month | ||||||||
| > 2,000 | 13 (15.5) | 7 (8.9) | 14 (17.1) | 14 (16.7) | 11 (12.9) | 16 (18.6) | 22 (25.6) | 25 (29.1) |
| 1,001–2,000 | 9 (10.7) | 4 (5.1) | 4 (4.9) | 8 (9.5) | 3 (3.5) | 5 (5.8) | 3 (3.5) | 2 (2.3) |
| 501–1,000 | 11 (13.1) | 6 (7.6) | 13 (15.9) | 11 (13.1) | 13 (15.3) | 7 (8.1) | 3 (3.5) | 4 (4.7) |
| 101–500 | 4 (4.8) | 17 (21.5) | 8 (9.8) | 6 (7.1) | 8 (9.4) | 1 (1.2) | 1 (1.2) | 1 (1.2) |
| ≤ 100 | 2 (2.4) | 3 (3.8) | 3 (3.7) | 3 (3.6) | 4 (4.7) | 3 (3.5) | 2 (2.3) | 2 (2.3) |
Abbreviations: AFP, alpha-fetoprotein; CA125, cancer antigen 125; CA19-9, cancer antigen 19-9; CEA, carcinoembryonic antigen; Labs, laboratories; PSA, prostate-specific antigen; TSH, thyroid-stimulating hormone; T3, triiodothyronine; T4, thyroxine.
Lab Med Online 2023;13:324~331 https://doi.org/10.47429/lmo.2023.13.4.324
© Lab Med Online